[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369449-105":59,"doc-detail-369449-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","harnessing-engineered-extracellular-vesicles-for-enhanced-therapeutic-efficacy-advancements-in-cancer-immunotherapy","Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy","","Extracellular vesicles (EVs), especially engineered variants, are emerging as promising cancer immunotherapy tools by modulating immune responses and delivering therapeutics with high specificity and low toxicity. Nanometer-sized EVs, including exosomes and related subtypes, naturally support intercellular communication and transport proteins, lipids, RNAs, and metabolites. Recent progress in engineered EV biogenesis, surface and cargo design, and passive/active targeting strengthens anti-tumor immunity and addresses the immunosuppressive tumor microenvironment (TME). The review summarizes these developments and discusses clinical translation challenges including scalability, safety, and targeted delivery, outlining future research priorities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/harnessing-engineered-extracellular-vesicles-for-enhanced-therapeutic-efficacy-advancements-in-cancer-immunotherapy/369449/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/harnessing-engineered-extracellular-vesicles-for-enhanced-therapeutic-efficacy-advancements-in-cancer-immunotherapy/369449.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are engineered extracellular vesicles considered promising for cancer immunotherapy?","Question",{"text":112,"@type":113},"They can modulate immune responses and deliver therapeutic agents with high specificity while minimizing toxicity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What kinds of cargo can extracellular vesicles carry in engineered therapies?",{"text":117,"@type":113},"Engineered EVs can transport diverse bioactive molecules such as proteins, lipids, RNAs, and metabolites.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges must be addressed for clinical translation of EV-based therapies?",{"text":121,"@type":113},"The review highlights issues related to scalability, safety, and achieving targeted delivery.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369449,1790319830,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Gong et al. J Exp Clin Cancer Res (2025) 44:138 [https://doi.org/10.1186/s13046-025-03403-w](https://doi.org/10.1186/s13046-025-03403-w)  \nJournal of Experimental & Clinical Cancer Research  \n REVIEW Open Access  \nHarnessing engineered extracellular  \nvesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy  \nZheng Gong1†, Cheng Cheng2†, Chaonan Sun3* and Xiaoli Cheng2*  \nAbstract  \nExtracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability to modulate immune responses and deliver therapeutic agents with high specificity and minimal toxicity. These nanometer-sized vesicles, which include exosomes (Exos) and other subtypes, naturally participate in intercellular communication and are capable of carrying a diverse range of bioactive molecules, including proteins, lipids, RNAs, and metabolites. Recent advancements in the biogenesis of engineered  \nEVs, such as strategies to modify their surface characteristics and cargo, have significantly expanded their potential as effective vehicles for targeted cancer therapies. Tailoring the contents of EVs, such as incorporating immunomodulatory molecules or gene-editing tools (GETs), has shown promising outcomes in enhancing anti-tumor immunity and overcoming the immunosuppressive tumor microenvironment (TME) . Moreover, optimizing delivery mechanisms, through both passive and active targeting strategies, is crucial for improving the clinical efficacy of EV-based therapies. This review provides an overview of recent developments in the engineering of EVs for cancer immunotherapy, focusing on their biogenesis, methods of content customization, and innovations in cargo delivery. Additionally, the review addresses the challenges associated with the clinical translation of EV-based therapies, such as issues related to scalability, safety, and targeted delivery. By offering insights into the current state of the field and identifying key areas for future research, this review aims to advance the application of engineered EVs in cancer treatment. Keywords Extracellular Vesicles (EVs), Engineered EVs, Cancer immunotherapy, Drug delivery, Therapeutics  \n†Zheng Gong and Cheng Cheng co-first author and contributed equally to this work.  \n*Correspondence:  \nChaonan Sun [13674138643@163.com](13674138643@163.com)[ ](13674138643@163.com)Xiaoli Cheng [chengxiaoli057509@163.com](chengxiaoli057509@163.com)  \n1 Department of Radiology, Shengjing Hospital of China Medical University, Liaoning Province, Shenyang 110004, China  \n2 Department of Cardiology, Shengjing Hospital of China Medical University, Liaoning Province, Shenyang 110004, China  \n3 Department of Radiation Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning 110042, China  \nIntroduction  \nCancer continues to represent a major global health challenge and remains one of the leading causes of death, with its incidence steadily increasing worldwide. According to the 2025 Global Cancer Statistics, solid tumors account for approximately 90% of all cancer diagnoses but comprise only 40% of clinical trials, most of which are still in the early stages of development [1, 2] . This discrepancy underscores the significant challenges in effectively treating solid tumors with existing therapeutic strategies. While traditional treatments such as surgery, chemotherapy, and radiotherapy are essential components of cancer management, they possess inherent limitations. Despite advancements  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if chang","cbCaijnRcR6ocaJP","https://ap.wps.com/l/cbCaijnRcR6ocaJP","pdf",4402389,32,"English","# Abstract\n# Introduction","[{\"question\":\"Why are engineered extracellular vesicles considered promising for cancer immunotherapy?\",\"answer\":\"They can modulate immune responses and deliver therapeutic agents with high specificity while minimizing toxicity.\"},{\"question\":\"What kinds of cargo can extracellular vesicles carry in engineered therapies?\",\"answer\":\"Engineered EVs can transport diverse bioactive molecules such as proteins, lipids, RNAs, and metabolites.\"},{\"question\":\"What challenges must be addressed for clinical translation of EV-based therapies?\",\"answer\":\"The review highlights issues related to scalability, safety, and achieving targeted delivery.\"}]","Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy | PDF",1790182739,81,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/477592b539743fc931c1c41c8c9bc89f.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbbd203759d6abaf7edbdecb7568264f.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecac1e1584d7e41449297244837c1b5c.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df80fd7833877e745758fe85ac48528d.webp",980,1301]